Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT05628870RecruitingPhase 1
Testing HRS-1358 for breast cancer that has spread
This early-phase study tests HRS-1358 tablets in people with breast cancer that is locally advanced or has spread. It may help learn whether the drug can control cancer, while also checking safety and how the body handles it.
Beijing, Beijing MunicipalityAges 18–75 - NCT06727227Recruiting
Study of Enhertu for HER2-low breast cancer
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
Panagyurishte, PazardzhikAges 18 years+ - NCT06738459Recruiting
Matching lymph node tests in breast cancer
This study looks back at past MRI scans and lymph node biopsies or surgeries in people with breast cancer to better understand how cancer spreads to the lymph nodes. If you had these tests as part of your care, your data might help improve future treatment decisions.
VillachAges 18 years+ - NCT07050433Recruiting
A study for men with advanced prostate cancer on a specific clinical trial
This study looks at men with metastatic castration-resistant prostate cancer who are already taking part in the SYNGERY-201 clinical trial. The goal is to understand how treatments work and how to best support patients.
San Francisco, CaliforniaAges 18 years+ - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT07260435RecruitingPhase 3
Shorter hormone treatment for low volume spread prostate cancer
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
AlkmaarAges 18 years+ - NCT07363486RecruitingPhase 1/Phase 2
Study of 225Ac-LNC1011 for advanced prostate cancer
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
Fuzhou, FujianAges 18–90 - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07606599RecruitingPhase 3
New drug BL-M07D1 for advanced biliary tract cancer
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
Hefei, AnhuiAges 18–75 - NCT06482073Recruiting
Genetic testing for lung cancer risk
This study tests blood, saliva, or tissue samples from people who have a lung nodule or suspected lung cancer. The goal is to find genetic changes that could guide personalized treatment or early detection.
Rochester, MinnesotaAges 18 years+ - NCT04796818Recruiting
MRI scan to track response in colorectal liver metastases
This study uses a special MRI scan to see how colorectal cancer in the liver responds to planned chemotherapy before and after surgery. It may help doctors better measure treatment success and plan care.
Houston, TexasAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT03582124RecruitingPhase 1/Phase 2
Panitumumab dye to help find lung cancer during surgery
This trial tests a special dye drug (panitumumab-IRDye800) that may help surgeons better see lung cancer areas while operating. If it works, it could improve how well cancer tissue is found and removed during planned lung surgery.
Palo Alto, CaliforniaAges 19 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+ - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT05914974Recruiting
Tracking inflammation changes during immunotherapy in gynecologic cancer
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
TübingenAges 18 years+ - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT05741242Enrolling by invitationPhase 1/Phase 2
Vaccine trial using customized immune targets for solid tumors
This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.
Beverly Hills, CaliforniaAges 12 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,872 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.